Thus, it can be reasonably expected that a clinical-grade DHODH inhibitor combined with venetoclax might improve outcomes for HGBCL patients, as well as other cancers with high expression of MYC and BCL2 or MYC and MCL-1. Here, BCL2 is linked to cancer.